PARNASSUS INVESTMENTS, LLC has added 6,868,459 shares of $BSX to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 09-30-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $BSX.
BOSTON SCIENTIFIC Hedge Fund Activity
We have seen 882 institutional investors add shares of BOSTON SCIENTIFIC stock to their portfolio, and 654 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 20,286,637 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $2,178,987,680
- EDGEWOOD MANAGEMENT LLC added 6,951,450 shares (+inf%) to their portfolio in Q2 2025, for an estimated $746,655,244
- PARNASSUS INVESTMENTS, LLC added 6,868,459 shares (+42978.9%) to their portfolio in Q3 2025, for an estimated $670,567,652
- JPMORGAN CHASE & CO removed 5,862,792 shares (-18.6%) from their portfolio in Q2 2025, for an estimated $629,722,488
- BLACKROCK, INC. added 5,016,674 shares (+3.5%) to their portfolio in Q2 2025, for an estimated $538,840,954
- VOYA INVESTMENT MANAGEMENT LLC removed 4,362,310 shares (-49.9%) from their portfolio in Q3 2025, for an estimated $425,892,325
- MILLENNIUM MANAGEMENT LLC removed 3,708,137 shares (-44.4%) from their portfolio in Q2 2025, for an estimated $398,290,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BOSTON SCIENTIFIC Insider Trading Activity
BOSTON SCIENTIFIC insiders have traded $BSX stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 4 sales selling 328,886 shares for an estimated $33,903,109.
- JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 7 sales selling 256,372 shares for an estimated $26,574,358.
- ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) has made 0 purchases and 2 sales selling 34,627 shares for an estimated $3,578,501.
- EDWARD J LUDWIG has made 0 purchases and 2 sales selling 8,000 shares for an estimated $842,488.
- VANCE R BROWN (SVP, GC and Corp. Secretary) sold 4,826 shares for an estimated $513,582
- JOHN BRADLEY SORENSON (EVP, Global Operations) sold 4,572 shares for an estimated $477,956
- YOSHIAKI FUJIMORI sold 2,901 shares for an estimated $310,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BOSTON SCIENTIFIC Government Contracts
We have seen $19,182,235 of award payments to $BSX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- Y90 GLASS MICROSPHERES: $1,197,000
- THERASPHERE Y-90: $963,835
- THERASPHERE Y90 TREATMENTS.: $720,000
- Y90 THERASPHERE: $675,325
- YTTRIUM-90 THERASPHERES: $532,500
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BOSTON SCIENTIFIC Congressional Stock Trading
Members of Congress have traded $BSX stock 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 07/31, 06/26, 06/11, 05/13, 04/28.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BOSTON SCIENTIFIC Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 10/23/2025
- Truist Securities issued a "Buy" rating on 10/23/2025
- BTIG issued a "Buy" rating on 10/22/2025
- Needham issued a "Buy" rating on 10/17/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Leerink Partners issued a "Outperform" rating on 10/01/2025
- Baird issued a "Outperform" rating on 10/01/2025
To track analyst ratings and price targets for BOSTON SCIENTIFIC, check out Quiver Quantitative's $BSX forecast page.
BOSTON SCIENTIFIC Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 15 analysts offer price targets for $BSX in the last 6 months, with a median target of $128.0.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $130.0 on 10/23/2025
- Patrick Wood from Morgan Stanley set a target price of $130.0 on 10/23/2025
- Larry Biegelsen from Wells Fargo set a target price of $125.0 on 10/23/2025
- Danielle Antalffy from UBS set a target price of $140.0 on 10/23/2025
- William Plovanic from Canaccord Genuity set a target price of $132.0 on 10/23/2025
- Marie Thibault from BTIG set a target price of $132.0 on 10/22/2025
- Mike Matson from Needham set a target price of $121.0 on 10/17/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $BSX ticker page for more data.
